Abstract Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive weakness, muscle atrophy, and paralysis due to the loss of upper and lower motoneurons (MNs). Sigma-1 receptor (sigma-1R) activation promotes neuroprotection after ischemic and traumatic injuries to the central nervous system. We recently reported that sigma-1R agonist (PRE-084) improves the survival of MNs after root avulsion injury in rats. Moreover, a mutation of the sigma-1R leading to frontotemporal lobar degeneration/amyotrophic lateral sclerosis (ALS) was recently described in human patients. In the present study, we analyzed the potential therapeutic effect of the sigma-1R agonist (PRE-084) in the SOD1 G93A mouse model of ALS. Mice were daily administered with PRE-084 (0.25 mg/kg) from 8 to 16 weeks of age. Functional outcome was assessed by electrophysiological tests and computerized analysis of locomotion. Histological, immunohistochemical analyses and Western blot of the spinal cord were performed. PRE-084 administration from 8 weeks of age improved the function of MNs, which was manifested by maintenance of the amplitude of muscle action potentials and locomotor behavior, and preserved neuromuscular connections and MNs in the spinal cord. Moreover, it extended survival in both female and male mice by more than 15 %. Delayed administration of PRE-084 from 12 weeks of age also significantly improved functional outcome and preservation of the MNs. There was an induction of protein kinase C-specific phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor in SOD1
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disorder characterized by progressive muscle atrophy and paralysis due to death of upper and lower MNs [1] . The majority ALS cases are sporadic with unknown etiology, whereas 10 % of cases correspond to inherited forms of ALS. Among these cases, mutations in the gene encoded for the enzyme Cu/Zn superoxide dismutase 1 (SOD1) are observed in approximately 20 % [2] . Based on these genetic mutations, transgenic animal models have been developed for the study of ALS. The most widely used model is a transgenic mouse with a glycine-to-alanine conversion at the 93rd codon of the SOD1 gene in high copy number (SOD1 G93A ) [3] . The phenotype of this mice recapitulates several clinical and histopathological features of both familial and sporadic forms of the human disease [3] . Moreover, it has been recently reported that alterations of the SOD1 protein are also related to sporadic ALS cases [4] , increasing the interest in the study of transgenic animals.
Several studies using ALS animal models have hypothesized that ALS pathogenesis might be related to glutamate excitotoxicity, oxidative stress, protein misfolding, mitochondrial defects, impaired axonal transport, and inflammation, with all of these factors contributing to MN death [5] .
The sigma-1R is a transmembrane protein found in the endoplasmic reticulum [6, 7] , which is highly expressed in MNs and other cells in the spinal cord [6, [8] [9] [10] . This receptor has the ability to translocate from the endoplasmic reticulum to the plasma membrane and mitochondria-associated membranes [7, 11, 12] . In the nervous system, sigma-1R mediates regulation of several processes, such as neuritogenesis, K + channels, and N-methyl-D-aspartate (NMDA) receptors activity, Ca 2+ homeostasis, and microglial activity. Furthermore, it is related to some central nervous system pathologies, including depression, schizophrenia, drug addiction, and Alzheimer disease [13] [14] [15] [16] . Several studies have demonstrated potent therapeutic actions of sigma-1R agonists, reducing glutamate-mediated cell death [17, 18] or modulating the inflammatory reaction after stroke in rats [19, 20] . Luty et al. [21] and Al-Saif et al. [22] recently reported a novel mutation of sigma-1R in patients affected by ALS, suggesting that pharmacological interventions targeting this receptor could be a good therapeutic approach.
We have previously reported the role of the selective sigma-1R agonist 2-(4-morpholi-nethyl)1-phenylcyclohexanecarboxylate (PRE-084) in motoneuron death. We demonstrated that PRE-084 administration promotes neuroprotection and neurite elongation through protein kinase C (PKC) on MNs in an in vitro organotypic model of excitotoxic lesion [18] . Moreover, administration of PRE-084 prevented spinal MNs death after spinal root avulsion in rats [10] . Therefore, the aim of this study was to assess the potential therapeutic effect of the sigma-1R agonist in the SOD1 mouse model of ALS.
Material and Methods

Transgenic Mice and Drug Administration
Transgenic mice with the G93A human SOD1 mutation (B6SJL-Tg[SOD1-G93A]1Gur) were obtained from the Jackson Laboratory (Bar Harbor, ME), and maintained at the Animal Service of the Universidad de Zaragoza. Hemizygote B6SJL SOD1 G93A males were obtained by crossing with B6SJL females from the CBATEG (Barcelona, Spain). The offspring was identified by polymerase chain reaction (PCR) amplification of DNA extracted from the tail tissue. All experimental procedures were approved by the Ethics Committee of the Universitat Autònoma de Barcelona.
Animals were evaluated at 8 weeks (prior to drug administration) by electrophysiological tests to obtain baseline values, and as a diagnostic test to distribute them between the experimental groups. PRE-084 and BD-1036 (Tocris Bioscience, Ellisville, MO) were used as sigma-1R agonist and antagonist, respectively. Both drugs were dissolved in saline and administered daily by intraperitoneal injections at 0.25 mg/kg. The experimental groups included in the study are summarized in Table 1 .
Nerve Conduction Tests
Motor nerve conduction tests were performed at 8 weeks of age and then every 2 weeks until 16 weeks in all the animals used in the study (Table 1 ). The sciatic nerve was percutaneously stimulated by means of single pulses of 0.02 ms duration (grass S88) delivered through a pair of needle electrodes placed at the sciatic notch. The compound muscle action potential (CMAP) (M wave) and the reflex H wave were recorded from the tibialis anterior (TA) and the plantar (interossei) muscles with microneedle electrodes [23, 24] . All potentials were amplified and displayed on a digital oscilloscope (Tektronix 450S; Tektronix, Beaverton OR, USA) at settings appropriate to measure the amplitude from baseline to the maximal negative peak. To ensure reproducibility, the recording needles were placed under the microscope to secure the same placement on all animals guided by anatomical landmarks. During the tests, the mice body temperature was kept constant between 34 and 36ºC by means of a thermostated heating pad.
Treadmill Test
The DigiGait system (DigiGait Imaging System, Mouse Specifics, Boston, MA) was used to assess the locomotor performance of the animals at the end-stage of the disease (at 16 weeks of age). All the animals used in the study (Table 1) were tested. The animals were placed on the treadmill belt and their capacity to run with increasing velocity was recorded. Treadmill speeds used were 5, 10, 15, 20, 25, and 30 cm/s, based on previous studies performed in our laboratory [25] . One slide of each animal was rehydrated for 1 min and stained for 2 h with an acidified solution of 3.1 mM cresyl violet. Then the slides were washed in distilled water for 1 min, dehydrated and mounted with DPX (Fluka, Buchs, Switzerland). MNs were identified by their localization in the ventral horn of the stained spinal cord sections and counted after strict size and morphological criteria (only MNs with diameters larger than 20 μm and with polygonal shape and prominent nucleoli were counted) [10] . The number of MNs present in both ventral horns was counted in 4 serial sections of each L4 to L5 segments [10, 23] .
To estimate the number of MNs innervating the TA muscle, retrograde-labeled MNs were counted under epifluorescence microscopy from slides 1, 3, 5, 7, and 9. The total number of MNs was calculated according to the formula of Abercrombie [26] .
Another series of sections was blocked with PBS-Tritonfetal bovine serum (FBS) and incubated overnight at 4°C with primary antibodies anti-glial fibrillary acidic protein (1:1000, Dako, Glostrup, Denmark), rabbit anti-ionized calcium binding adaptor molecule 1 (1:1000, Wako, Chemicals, Richmond, VA, USA), anti-sigma-1R (1:500, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), anti-phospho-NR1 (Ser896) (1:500, Millipore, Billerica, MA, USA), or anti-phospho-NR1 (Ser897) (1:500, Millipore). After washes, sections were incubated for 1 h at room temperature with Cy2-or Cy3-conjugated secondary antibody (1:200; Jackson Immunoresearch, West Grove, PA, USA), or, in the case of anti-phospho-NR1 antibodies, with biotinilated secondary antibody (1:200, Vector, Burlingame, CA, USA) and then for 2 h at room temperature with Cy3-conjugated streptavidin (1:1000, Vector). For colocalizations, spinal MNs were labeled with Cy2-or Cy3-conjugated fluorotracer Nissl staining (1:200, Life Technologies, Grand Island, NY, USA). To quantify astroglial and microglial immunoreactivity, microphotographs of the grey matter of the ventral horn were taken at×400 and, after defining the threshold for background correction, the integrated density of glial fibrillary acidic protein (GFAP) or ionized calcium binding adaptor molecule 1 (Iba1) labeling was measured using ImageJ software (National Institutes of Health, Bethesda, MA, USA) [27, 28] . The integrated density is the area above the threshold for the mean density minus the background.
Protein Extraction and Western Blot
For protein extraction, a subset of mice (4 of each experimental group) were anesthetized and decapitated at 16 weeks of age. The lumbar spinal cord was removed and divided into quarters to isolate the ventral parts. One of these parts was prepared for protein extraction and homogenized in modified radioimmunoprecipitation assay buffer (50 mM Tris-HCl pH7.5, 1 % Triton X-100, 0.5 % sodium deoxycholate, 0.2 % sodium dodecyl sulfate (SDS), 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA)) adding 10 μl/ml of Protease Inhibitor cocktail (Sigma, St Louis, MO, USA) and 1 mM sodium orthovanadate (phosphatase inhibitor) (Roche, Manheim, Germany). After clearance, protein concentration was measured by bicinchoninic acid assay (BCA Protein Assay Kit, Pierce, Rockford, IL).
To perform the Western blot, 30 μg of protein of each sample were loaded in 7.5 % SDS-poliacrylamide gels. The transfer buffer was 25 mM trizma-base, 192 mM glycine, 20 % (v/v) methanol, pH8.4. The membranes were incubated with 5 % bovine serum albumin in PBS plus 0.05 % Tween-20 for 1 h, and then with primary antibodies at 4°C overnight. The primary antibodies used were: anti-b-actin (Sigma; 1:10000), anti-sigma-1R (Santa Cruz, 1:500), anti-NMDAR1 (Millipore, 1:500), anti-phospho NR1 (S896) (Millipore, 1:500), or antiphospho NR1 (S897) (Milllipore, 1:500). Horseradish peroxidase, coupled with secondary antibody incubation was performed for 90 min at room temperature. The membranes were visualized using an enhanced chemiluminiscence method and the images were collected and analyzed with Gene Genome apparatus and Gene Snap and Gene Tolls softwares (Syngene, Cambridge, UK), respectively.
Survival
A subset (of 10 mice of each group and gender) was used to assess the effects of treatment on survival of the animals. It was considered that animals reached the endpoint of the disease when they were unable to stand up for 30 s when placed on their side.
Statistical Analysis
Data are expressed as mean ± SEM. Electrophysiological and locomotion test results were statistically analyzed using repeated measurements and 1-way analysis of variance, applying the Bonferroni post-hoc test when necessary. Histological data were analyzed using the Mann-Whitney U test. Survival data was analyzed using the Kaplan-Meir test.
Results
Sigma-1R Expression in SOD1 Animals
We studied the sigma-1R expression levels and localization in the ventral spinal cord of mice aged 16 weeks to assess whether MNs could be directly affected by the PRE-084 administration. Western blot analysis revealed that the expression levels of the receptor were not altered during disease progression because there were no differences in the amount of protein between experimental groups (Fig. 1A) . Furthermore, immunohistochemistry revealed co-labeling between Nissl staining (labeling MNs) and sigma-1R (Fig. 1B) , indicating that this receptor is expressed in the MNs of both wild-type and transgenic animals.
PRE-084 Administration Improves Spinal Motoneuron Function in SOD1 Animals
The analysis of lower MN functional activity is crucial to assess the effect of new treatments, because the loss of neuromuscular function is 1 of the hallmarks of the disease process in ALS animal models [29] [30] [31] . The results showed that PRE-084 administration significantly improved the amplitude of TA and plantar compound muscle action potential (CMAP), both in female and male SOD1 G93A mice from 12 weeks of age compared to untreated mice. This effect was sustained until the end of the follow-up (16 weeks of age) when the mean amplitude of the potentials was twice that of the untreated animals. The functional preservation was especially marked in the TA muscle, because at the end of the follow-up its function was 80 % of the baseline values recorded in the pre-treatment 8-weeks test. Coadministration of the sigma-1R antagonist BD-1036 reverted the improvement achieved by the PRE-084 agonist (Fig. 2) .
PRE-084 Treatment Improves Locomotor Performance in SOD1 Animals
PRE-084 administration also significantly improved the locomotor performance of SOD1 animals (Kaplan-Meier test; p<0.05). Both male and female mice administered with the sigma-1R agonist were able to run at higher speeds compared to untreated mice. The performance of untreated SOD1 animals began to decline from 10 cm/s and none were able to run at 30 cm/s (the maximum speed tested). However, animals treated with PRE-084 did not show locomotor impairments until 25 cm/s, and approximately half of them were able to maintain locomotor performance at 30 cm/s at 16 weeks of age. Again the beneficial effects were blocked when the sigma-1R antagonist was coadministered ( Fig. 3) . 
PRE-084 Administration Preserves Neuromuscular Connections in SOD1 Animals
To assess whether PRE-084 administration could maintain the connection between MNs and the skeletal muscles, retrotracers were injected in the TA muscle at 15 weeks and the number of stained MNs in the spinal cord counted 1 week later. The results showed that sigma-1R agonist administration significantly preserved the number of MNs innervating the TA muscle (Fig. 4) . PRE-084 treated animals showed 40 % higher number of labeled MNs in the spinal cord with respect to SOD1 untreated mice. This beneficial effect was reverted by coadministration of the sigma-1R antagonist. Figure 4A shows representative images of the cord ventral horns of untreated (SOD1c), treated with PRE-084, and cotreated with PRE-084 and BD-1036 SOD1 transgenic mice.
PRE-084 Administration Preserves Motoneurons in the Anterior Horn of the Lumbar Spinal Cord
The survival of spinal MNs was assessed by counting the number of stained MNs soma in the anterior horns of the lumbar spinal cord in mice of 16 weeks of age, focusing in L4 to L5 segments where the TA and the plantar muscles motor nuclei are represented [32] . MN counts were restricted to the lateral area of the ventral horn lamina IX, because this population innervates the hind-limb muscles. Neurons smaller than 20 μm in diameter were excluded from counting, even if they could be atrophic MNs because they were unlikely to be functional.
PRE-084 administration reduced the neurodegenerative process in SOD1 mice (Fig. 5) . Treated animals showed a 30 % increase in the number of MNs present in the ventral spinal horns, without differences between males and females. Alhough SOD1 untreated animals had 16.1±1.6 (male) and 20.1±1.1 (female) MNs per section, PRE-084 treated mice had 34.8±0.9 and 33.9± 2.1, respectively. The coadministration of the sigma-1R antagonist blocked the neuroprotective effect achieved by the agonist (Fig 5B) . Figure 5A shows representative images of ventral horns of wild-type, untreated control, treated with PRE-084, and co-treated with PRE-084 and BD-1036 SOD1 mice to illustrate the neuroprotective effect.
PRE-084 Administration Reduces Microglial but Not Astroglial Immunoreactivity in the SOD1 Spinal Cord
It has been extensively reported that glial cells contribute to MN degeneration, both in animal models [33] [34] [35] and in ALS patients [36] . Thus, we analyzed both The results showed that PRE-084 administration significantly reduced microglial, but not astroglial immunoreactivity in the ventral horn of SOD1 animals (Figs. 6 and 7), whereas in both male and female untreated SOD1 mice, Iba-1 immunoreactivity was increased by more than 600 % compared to wild-type mice, PRE-084 treatment reduced it to approximately 300 %. This improvement was reverted when the sigma-1R antagonist was coadministered.
PRE-084 Delayed Treatment Also Produces Functional Improvement in SOD1 Animals
Considering the important effect achieved by the sigma-1R agonist administered from 8 weeks of age (i.e., a presymptomatic stage), we studied that if a more delayed treatment (i.e., from the 12th week) could also ameliorate the animals condition. Electrophysiological tests revealed that PRE-084 treatment produced a The graphs represent the proportion of animals that were able to run with increasing velocity and evidence the larger proportion of PRE-084 treated animals that were able to run at higher speeds (Kaplan-Meier test; chi-square017.27, p< 0.001 for females; chi-square014.96, p<0.001 for males). (B) Representative images of SOD1 untreated animals (SOD1c) and treated animals with PRE-084 (PRE) running at 10 cm/s. Note the misplacement of both paws (black dots) in the untreated SOD1 mouse and the reversion of this sign achieved by PRE-084 administration significant increase of the TA CMAP from 14 weeks, with a maximum effect at the end of the follow-up, when the mean amplitude was 25 % higher than in untreated SOD1 mice (Fig. 8A) . The delayed treatment also improved the locomotor performance of the animals (Kaplan-Meier test, p<0.05), whereas SOD1 untreated animals performance declined from 10 cm/seconds to all treated mice supported until 15 cm/seconds. At 30 cm/ seconds, when SOD1 controls were completely unable to perform the test, 42 % of the treated animals were able to run (Fig. 8B) . MN counts revealed that delayed administration of the sigma-1R agonist produced a significant 13 % increase in the number of stained MN in the anterior horns of spinal cord sections compared to SOD1 untreated mice (Fig. 8C ).
Sigma-1R Agonist Significantly Extends Survival of SOD1 Transgenic Mice
The administration of PRE-084 from 8 weeks of age significantly prolonged survival of both female and male SOD1 mice (Kaplan-Meir analysis, p<0.001), whereas untreated female and male SOD1 mice lived 124.1±0.96 and 122.6± 3.06 days, respectively, and treated animals survived for 140.5±1.77 and 133.1±3.91 days (approximately 15 and 10 % longer) (Fig. 9) . Previously reported, in vitro studies indicate that the sigma-1R agonist suppresses NMDA currents in rat retinal ganglion cells [14] and rescues MNs from excitotoxic-induced death mediated by PKC activation [18] . Thus, we assessed if PRE-084 might exert its therapeutic effect in vivo through modulation of NMDA receptors via PKC. To assess this hypothesis, we analyzed the phosphorylation state of 2 PKC-specific Sigma-1R Agonist Treatment in ALS Miceserines (Ser896 and Ser897) in the NR1 subunits of NMDA receptors. Because there were no differences between males and females in the functional and histological results, data from both genders was pooled. The results showed a significant increase in the phosphorylation of PKC-specific Ser896 and Ser897 of the NMDA-NR1 subunit in mice treated with the sigma-1R agonist, by 4.3-and 5.5-fold with respect to SOD1 untreated animals, respectively. The coadministration of the sigma-1R antagonist reduced the amount of phosphorylated NR1 to control values (Fig. 10A) . To assess whether the phosphorylation was affecting the receptors expressed in MNs, we performed immunohistochemical colocalization of the phopho-NR1 subunits and the MNs in the lumbar spinal cord. Results revealed that both PKC-specific NR1 phosphorylations were exclusively present in MNs of PRE-084-treated SOD1 animals (Fig. 10B) .
Discussion
In this study we have analyzed the effect of the sigma-1R agonist, PRE-084, as a treatment for the SOD1 G93A mouse G93A -treated animals compared with SOD1 G93A -untreated mice.
We previously reported the beneficial role of PRE-084 in terms of neuroprotection on both in vitro and in vivo models of MN death. First we demonstrated that PRE-084 promotes MN survival and neurite outgrowth in an organotypic model of excitotoxic insult [18] . We have also shown a potent neuroprotective effect of PRE-084 treatment on spinal MNs after L4 to L5 root avulsion injury in adult rats [10] . Focusing on ALS, it has been recently described a causative relation of mutations in the SIGMA-R1 gene in human patients developing juvenile ALS and frontotemporal lobar degeneration-ALS pathology [21, 22] , suggesting that this receptor may be a good target for the treatment of ALS. First we assessed the expression levels and localization of the sigma-1R in the ventral part of the lumbar spinal cord of SOD1 G93A mice. Despite a slight reduction compared to wild-type mice, the results showed that sigma-1R was present in spinal MNs of SOD1 G93A animals, even at 16 weeks of age, pointing out that agonist administration can directly affect MNs. To confirm that the effects of the selective agonist PRE-084 were due to modulation of the sigma-1R, a selective antagonist (BD1036) was coadministered in another group of animals. This coadministration blocked all the beneficial effects, demonstrating that the therapeutic action can be attributed to the activation of the sigma-1R.
Abnormal function of spinal MNs, loss of neuromuscular junctions, and subsequent death of the MNs are key elements of the pathology in human patients and animal models of ALS [1, 29, 37] . Recently, we characterized the pattern of lower and upper MN dysfunction electrophysiologically [23] during disease progression in the SOD1 G93A mouse model, revealing that this is a reliable test to monitor the animal model, as well as human patients. In the present work, we found that daily sigma-1R agonist administration from 8 weeks of age, a time when signs of paresis are not present, yet but when nerve conduction tests clearly identify motor dysfunction, greatly improves the function of lower MN in both male and female SOD1 G93A mice, as evidenced by the amplitude of the CMAPs, especially in the TA muscle,which functioned at 16 weeks of age and was maintained compared to baseline values. This improved function correlated with the preservation of more than 70 % of spinal MNs, still innervating the TA muscle, twice as many as in the untreated SOD1 G93A animals (32 %). Gait abnormalities and progressive paralysis are also 2 main characteristics of ALS in human [1] and animal models [25] . We found a significant improvement in the locomotor capacity of SOD1 G93A mice treated with PRE-084 because they were able to run at higher speeds on a treadmill than untreated SOD1 G93A mice. This fact demonstrates that sigma-1R agonist administration preserves muscle strength and reduces signs of paralysis. Furthermore, it resulted in a significant prolongation for 16 and 11 days in survival of female and male SOD1 G93A mice, respectively. Therefore, sigma-1R modulation produces important functional benefits in terms of spinal MN function, locomotion, and survival in the SOD1 G93A mouse model, even comparatively better than silencing the mutant SOD1 expression [38] or other pharmacological treatments previously reported [39] , such as riluzole [40] .
Once demonstrated that daily PRE-084 administration from 8 weeks of age significantly improves functional performance and preserves MN in the spinal cord, we performed a second study in which PRE-084 was administered from 12 weeks, the beginning of the classical symptomatic phase in SOD1 G93A mice, to mimic the time point at which patients might start the treatment. The results showed that delayed administration was also able to improve spinal MN function and locomotion performance, and significantly preserved MN cell bodies in the spinal cord compared to SOD1 G93A untreated animals. Sigma-1R ligands have been shown to promote neuroprotection in several types of insults [15] . In vitro studies revealed potent neuroprotective effects of sigma-1R agonists after excitotoxic damage [18] , hypoxia-mediated neurotoxicity [41] , oxidative stress-induced cell death [17] , or glucose deprivation [42] . In vivo studies demonstrated that sigma-1R agonists exert therapeutic actions in rats after stroke [19, 20] , after selective cholinergic lesions [43] , and after spinal root avulsion [10] . The results found in this study also reveal a potent neuroprotective effect of PRE-084 administration on spinal MNs in the neurodegenerative SOD1 G93A mice model. At 16 weeks of age, there was a 30 % increase in the number of surviving MNs in the spinal cord of both male and female SOD1 animals treated with PRE-084 with respect to untreated animals. We have previously described the progression of spinal MN degeneration of SOD1 G93A mice, showing that the number of surviving MNs per lumbar cord section averaged 37±2 and 33±3 in male and female mice, respectively, at 12 weeks of age, and 16±2 and 20±1 in male and female mice at 16 weeks of age [23, 44] , respectively. In the present study, we found that PRE-084 treated animals had a mean of 35±1 (males) and 34±2 (females) MNs per section at 16 weeks of age. Thus, sigma-1R agonist administration slows down the degenerative process so that treated animals have the same number of MNs per section at 16 weeks than untreated animals at 12 weeks. It has been extensively described that calcium dysregulation and excitotoxicity are 2 main pathogenic mechanisms of ALS pathology [45, 46] . ALS-vulnerable spinal and brainstem MNs display low endogenous Ca 2+ buffering capacity, that is 5 to 6 times lower than that found in ALSresistant MNs (i.e., oculomotor MNs), making them more susceptible to excitotoxic insults [47] . NMDA receptor is considered to be 1 of the key elements in excitotoxiciy [46] . It has been reported that sera from ALS patients induces abnormal NMDA receptor activation [48] . Moreover, Sunico et al. [49] showed an excitation/inhibition imbalance in MNs of SOD1 G93A mice with an increased density of glutamatergic synapses, which could lead to an enhancement of Ca 2+ influx into the cells. Thus, NMDA receptor modulation might be a good target to reduce MN damage. Sigma-1R agonists, such as SKF10097 and PRE-084, suppress NMDA currents in rat retinal ganglion cells through a PKC-dependent mechanism, leading to a reduction of calcium influx into the cytoplasm [14] . Furthermore, sigma-1R agonists prevent Ca 2+ dysregulation and promote neuroprotection in rat cortical neurons by modulating Ca 2+ influx through NMDA receptors [41] , and also protect MNs in organotypic cultures against excitotoxicity [18] . Our novel results show that sigma-1R agonist administration led to increased PKC-specific phosphorylation of NR1 subunits present in spinal MNs, demonstrating a direct effect of the treatment in these cells. These changes in the NMDA receptor might reduce its permeability and, thus, the calcium influx into the MNs, attenuating excitotoxicity. Further experiments should be performed to assess whether PRE-084 modifies the NMDA channel properties in SOD1 MNs.
Neuroinflammation, and particularly the role of microglia is another pathological hallmark of ALS [50] . In resting conditions, SOD1 transgenic microglia shows reduced neuroprotective properties [51] . Moreover, phagocytic microglia adjacent to MNs is present at the very early stages of the disease in the transgenic rat model of ALS [35] , suggesting that abnormal microglial function could play an active role in MN degeneration. Our results revealed a reduction of microglial immunoreactivity in the ventral spinal cord of PRE-084-treated SOD1 G93A mice compared to untreated SOD1 G93A mice. In vitro assays performed by Hall et al. [13] , in 2009, showed that the activation of sigma-1R suppresses adenosine triphosphate-induced Ca 2+ influx and attenuates microglial activation. Both findings point out that sigma-1R could directly modulate microglial activation in SOD1 G93A animals acting through a complementary non-neuronal pathway to ameliorate the MNs environment and promote their survival. This effect may add to the reduction of neuroinflammatory response, secondary to the prevention of motoneuron degeneration.
Our results demonstrate for the first time that a sigma-1R agonist has potent beneficial actions in the SOD1 G93A model of ALS. We show that PRE-084 may exert, at least, a dual therapeutic contribution, modulating the NMDA Ca 2+ influx to reduce excitotoxic damage to MNs, and the microglial reactivity to ameliorate the MNs environment. Such a plurifunctional target may provide better translational outcomes than drugs that act only on 1 of the multiple physiopathological mechanisms involved in ALS. These findings have increased importance because sigma-1R alterations have been reported in human patients, opening a novel perspective for the study of the potential role of sigma-1R agonists as therapeutic agents for ALS.
